Total Payments
$784,610
2024 Payments
$54,543
Companies
27
Transactions
1,035
Medicare Patients
2,004
Medicare Billing
$121,169
Payment Breakdown by Category
Consulting$611,494 (77.9%)
Other$78,912 (10.1%)
Travel$63,520 (8.1%)
Research$23,247 (3.0%)
Food & Beverage$7,436 (0.9%)
Education$2.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $611,494 | 213 | 77.9% |
| Travel and Lodging | $63,520 | 410 | 8.1% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $49,644 | 22 | 6.3% |
| Unspecified | $23,247 | 23 | 3.0% |
| Honoraria | $14,888 | 7 | 1.9% |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $14,380 | 3 | 1.8% |
| Food and Beverage | $7,436 | 356 | 0.9% |
| Education | $2.00 | 1 | 0.0% |
Payments by Type
General
$761,363
1,012 transactions
Research
$23,247
23 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ABBVIE INC. | $148,504 | 215 | $0 (2024) |
| Janssen Biotech, Inc. | $85,136 | 100 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $81,331 | 83 | $0 (2024) |
| UCB, Inc. | $57,442 | 37 | $0 (2024) |
| UCB SA | $51,823 | 48 | $0 (2024) |
| Amgen Inc. | $51,359 | 58 | $0 (2022) |
| Novartis Pharmaceuticals Corporation | $44,189 | 76 | $0 (2024) |
| LEO Pharma AS | $42,509 | 85 | $0 (2021) |
| Lilly USA, LLC | $41,161 | 21 | $0 (2019) |
| Eli Lilly and Company | $35,709 | 23 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $54,543 | 141 | E.R. Squibb & Sons, L.L.C. ($12,870) |
| 2023 | $67,981 | 130 | ABBVIE INC. ($23,756) |
| 2022 | $68,739 | 85 | E.R. Squibb & Sons, L.L.C. ($18,205) |
| 2021 | $70,903 | 41 | AbbVie Inc. ($17,635) |
| 2020 | $118,262 | 50 | UCB, Inc. ($19,038) |
| 2019 | $134,679 | 185 | AbbVie, Inc. ($38,322) |
| 2018 | $127,754 | 195 | Lilly USA, LLC ($27,349) |
| 2017 | $141,748 | 208 | Janssen Biotech, Inc. ($25,939) |
All Payment Transactions
1,035 individual payment records from CMS Open Payments — Page 1 of 42
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/10/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | SPEVIGO (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $298.71 | General |
| Category: IMMUNOLOGY | ||||||
| 12/03/2024 | Boehringer Ingelheim International GmbH | SPEVIGO (Drug) | Travel and Lodging | In-kind items and services | $1.68 | General |
| Category: IMMUNOLOGY | ||||||
| 11/11/2024 | Janssen Global Services, LLC | TREMFYA (Drug) | Consulting Fee | Cash or cash equivalent | $4,245.13 | General |
| Category: Immunology | ||||||
| 11/11/2024 | Janssen Global Services, LLC | TREMFYA (Drug) | Travel and Lodging | Cash or cash equivalent | $507.15 | General |
| Category: Immunology | ||||||
| 11/11/2024 | Janssen Global Services, LLC | TREMFYA (Drug) | Travel and Lodging | Cash or cash equivalent | $12.50 | General |
| Category: Immunology | ||||||
| 11/04/2024 | E.R. Squibb & Sons, L.L.C. | — | Consulting Fee | Cash or cash equivalent | $5,232.02 | General |
| 11/04/2024 | ABBVIE INC. | — | Consulting Fee | Cash or cash equivalent | $4,828.97 | General |
| 11/04/2024 | Boehringer Ingelheim International GmbH | SPEVIGO (Drug) | Consulting Fee | Cash or cash equivalent | $804.01 | General |
| Category: IMMUNOLOGY | ||||||
| 11/04/2024 | Boehringer Ingelheim International GmbH | SPEVIGO (Drug) | Consulting Fee | Cash or cash equivalent | $655.41 | General |
| Category: IMMUNOLOGY | ||||||
| 11/04/2024 | E.R. Squibb & Sons, L.L.C. | — | Travel and Lodging | In-kind items and services | $625.05 | General |
| 11/04/2024 | ABBVIE INC. | — | Travel and Lodging | In-kind items and services | $576.90 | General |
| 11/04/2024 | Incyte Corporation | — | Consulting Fee | Cash or cash equivalent | $305.00 | General |
| 11/04/2024 | UCB, Inc. | — | Food and Beverage | In-kind items and services | $148.54 | General |
| 11/04/2024 | Boehringer Ingelheim International GmbH | SPEVIGO (Drug) | Travel and Lodging | In-kind items and services | $78.30 | General |
| Category: IMMUNOLOGY | ||||||
| 11/04/2024 | Boehringer Ingelheim International GmbH | SPEVIGO (Drug) | Travel and Lodging | In-kind items and services | $78.30 | General |
| Category: IMMUNOLOGY | ||||||
| 11/04/2024 | E.R. Squibb & Sons, L.L.C. | — | Travel and Lodging | In-kind items and services | $15.01 | General |
| 11/04/2024 | ABBVIE INC. | — | Travel and Lodging | In-kind items and services | $12.73 | General |
| 11/04/2024 | Boehringer Ingelheim International GmbH | SPEVIGO (Drug) | Travel and Lodging | In-kind items and services | $2.26 | General |
| Category: IMMUNOLOGY | ||||||
| 11/04/2024 | Boehringer Ingelheim International GmbH | SPEVIGO (Drug) | Travel and Lodging | In-kind items and services | $1.89 | General |
| Category: IMMUNOLOGY | ||||||
| 11/04/2024 | Boehringer Ingelheim International GmbH | SPEVIGO (Drug) | Travel and Lodging | In-kind items and services | $0.51 | General |
| Category: IMMUNOLOGY | ||||||
| 11/04/2024 | Boehringer Ingelheim International GmbH | SPEVIGO (Drug) | Travel and Lodging | In-kind items and services | $0.38 | General |
| Category: IMMUNOLOGY | ||||||
| 11/03/2024 | Boehringer Ingelheim International GmbH | SPEVIGO (Drug) | Travel and Lodging | In-kind items and services | $6.45 | General |
| Category: IMMUNOLOGY | ||||||
| 11/03/2024 | Boehringer Ingelheim International GmbH | SPEVIGO (Drug) | Food and Beverage | In-kind items and services | $2.20 | General |
| Category: IMMUNOLOGY | ||||||
| 11/03/2024 | Boehringer Ingelheim International GmbH | SPEVIGO (Drug) | Food and Beverage | In-kind items and services | $1.06 | General |
| Category: IMMUNOLOGY | ||||||
| 10/03/2024 | Boehringer Ingelheim International GmbH | SPEVIGO (Drug) | Food and Beverage | In-kind items and services | $16.49 | General |
| Category: IMMUNOLOGY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A PHASE 3, MULTICENTER, randomized, double-blind, PLACEBO- AND ACTIVE COMPARATOR-CONTROLLED, parallel-group study to EVALUATE the EFFICACY AND safety of bimekizumab in adult subjects with moderate to | UCB, Inc. | $5,020 | 3 |
| A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND STUDY WITH A 24-WEEK ACTIVE-CONTROLLED INITIAL TREATMENT PERIOD FOLLOWED BY A 32-WEEK, DOSE-BLIND MAI | UCB, Inc. | $4,520 | 1 |
| A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, STUDY FOLLOWED BY A DOSE-BLIND PERIOD AND OPEN-LABEL FOLLOW-UP TO EVALUATE THE EFFICACY AND SAFETY OF CERTOLIZUMAB PEGOL IN SUBJECTS W | UCB, Inc. | $2,300 | 1 |
| A phase 3, MULTICENTER, double-blind, placebo controlled study with an Initial Treatment period FOLLOWED BY A randomized-withdrawal PERIOD TO EVALUATE THE EFFICACY and safety OF BIMEKIZUMAB IN ADULT S | UCB, Inc. | $2,300 | 1 |
| A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND STUDY WITH A 24-WEEK ACTIVE-CONTROLLED INITIAL TREATMENT PERIOD FOLLOWED BY A 32-WEEK, DOSE-BLIND MAINTENANCE TREATMENT PERIOD TO EVALUATE THE EFFICACY | UCB, Inc. | $1,640 | 4 |
| A 24-WEEK MULTICENTER, RANDOMIZED, BLINDED, PARALLEL-GROUP STUDY COMPARING THE EFFICACY AND SAFETY OF IXEKIZUMAB TO GUSELKUMAB IN PATIENTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS | Eli Lilly and Company | $1,103 | 1 |
| A Phase 3, Multi-Center, Randomized, Place-Controlled, Double-Blind, Study of the Efficacy and Safety of Apremilast (CC-10004 in subjects with Moderate to Sever Plaque Psoriasis of the Scap) (CC-10004-SPSO-001) | Celgene Corporation | $952.00 | 1 |
| A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, SECUKINUMAB-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BIMEKIZUMAB IN ADULT SUBJ | UCB, Inc. | $820.00 | 1 |
| A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, SECUKINUMAB-CONTROLLED, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BIMEKIZUMAB IN ADULT SUBJECTS WITH MODERATE TO SEVERE CHRONIC PLAQUE PSORIA | UCB, Inc. | $820.00 | 2 |
| A PHASE 3, MULTICENTER, randomized, double-blind, PLACEBO- AND ACTIVE COMPARATOR-CONTROLLED, parallel-group study to EVALUATE the EFFICACY AND safety | UCB, Inc. | $820.00 | 1 |
| Multicenter dose ranging study of the safety and efficacy of ENBREL in psoriasis | Amgen Inc. | $508.17 | 1 |
| CC-10004-SPSO-001 - A Phase 3, Multi-Center, Randomized, Place-Controlled, Double-Blind, Study of the Efficacy and Safety of Apremilast (CC-10004 in subjects with Moderate to Sever Plaque Psoriasis of the Scap) | Celgene Corporation | $442.00 | 1 |
| Comparative effectiveness of bimekizumab for the treatment of plaque psoriasis: a network meta-analysis | UCB, Inc. | $420.00 | 1 |
| Comparative Efficacy of Bimekizumab for the Treatment of Moderate to Severe Plaque Psoriasis: A Network Meta-Analysis | UCB, Inc. | $400.00 | 1 |
| A MULTICENTER STUDY WITH A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED INDUCTION DOSING PERIOD FOLLOWED BY A RANDOMIZED WITHDRAWAL MAINTENANCE DOSING PERIOD TO EVALUATE THE EFFICACY AND SAFETY OF MIRIKIZUMAB IN PATIENTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS OASIS-1 | Eli Lilly and Company | $282.38 | 1 |
| M15-997 | AbbVie, Inc. | $24.24 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 10 | 559 | 802 | $227,693 | $31,846 |
| 2022 | 9 | 523 | 1,160 | $222,855 | $35,620 |
| 2021 | 11 | 534 | 1,104 | $223,611 | $38,219 |
| 2020 | 8 | 388 | 545 | $115,055 | $15,484 |
Total Patients
2,004
Total Services
3,611
Medicare Billing
$121,169
Procedure Codes
38
All Medicare Procedures & Services
38 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 190 | 224 | $53,984 | $9,790 | 18.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 74 | 92 | $32,660 | $6,180 | 18.9% |
| J7308 | Aminolevulinic acid hcl for topical administration, 20%, single unit dosage form (354 mg) | Office | 2023 | 19 | 22 | $14,590 | $6,070 | 41.6% |
| 17000 | Destruction of precancer skin growth, 1 growth | Facility | 2023 | 76 | 85 | $30,855 | $2,788 | 9.0% |
| 17110 | Destruction of skin growth, 1-14 growths | Facility | 2023 | 48 | 50 | $31,800 | $2,336 | 7.3% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Facility | 2023 | 40 | 40 | $23,080 | $1,938 | 8.4% |
| 96567 | Application of light to destroy precancer skin growth | Office | 2023 | 14 | 15 | $11,430 | $1,468 | 12.8% |
| 11102 | Biopsy of related skin growth, first growth | Facility | 2023 | 32 | 35 | $19,670 | $610.24 | 3.1% |
| 17003 | Destruction of precancer skin growth, 2-14 growths | Facility | 2023 | 54 | 226 | $7,232 | $347.15 | 4.8% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Facility | 2023 | 12 | 13 | $2,392 | $319.08 | 13.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 200 | 259 | $60,606 | $11,370 | 18.8% |
| J7308 | Aminolevulinic acid hcl for topical administration, 20%, single unit dosage form (354 mg) | Office | 2022 | 19 | 21 | $13,363 | $6,148 | 46.0% |
| 96900 | Application of ultraviolet light to skin | Office | 2022 | 19 | 363 | $40,641 | $6,033 | 14.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 55 | 68 | $23,460 | $4,321 | 18.4% |
| 17000 | Destruction of precancer skin growth, 1 growth | Facility | 2022 | 80 | 99 | $34,848 | $3,482 | 10.0% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Facility | 2022 | 38 | 38 | $21,280 | $2,070 | 9.7% |
| 17110 | Destruction of skin growth, 1-14 growths | Facility | 2022 | 32 | 34 | $15,232 | $1,415 | 9.3% |
| 11102 | Biopsy of related skin growth, first growth | Facility | 2022 | 18 | 19 | $5,396 | $405.61 | 7.5% |
| 17003 | Destruction of precancer skin growth, 2-14 growths | Facility | 2022 | 62 | 259 | $8,029 | $375.60 | 4.7% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 188 | 240 | $54,733 | $10,369 | 18.9% |
| J7308 | Aminolevulinic acid hcl for topical administration, 20%, single unit dosage form (354 mg) | Office | 2021 | 17 | 22 | $13,518 | $6,868 | 50.8% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 67 | 93 | $31,155 | $6,348 | 20.4% |
| 96900 | Application of ultraviolet light to skin | Office | 2021 | 19 | 329 | $35,961 | $5,753 | 16.0% |
| 17000 | Destruction of skin growth | Facility | 2021 | 68 | 81 | $27,702 | $2,692 | 9.7% |
| 99203 | New patient outpatient visit, total time 30-44 minutes | Facility | 2021 | 36 | 36 | $19,424 | $2,039 | 10.5% |
About Dr. Kenneth Gordon, M.D
Dr. Kenneth Gordon, M.D is a Dermatology healthcare provider based in Wauwatosa, Wisconsin. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/16/2006. The National Provider Identifier (NPI) number assigned to this provider is 1790865806.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Kenneth Gordon, M.D has received a total of $784,610 in payments from pharmaceutical and medical device companies, with $54,543 received in 2024. These payments were reported across 1,035 transactions from 27 companies. The most common payment nature is "Consulting Fee" ($611,494).
As a Medicare-enrolled provider, Gordon has provided services to 2,004 Medicare beneficiaries, totaling 3,611 services with total Medicare billing of $121,169. Data is available for 4 years (2020–2023), covering 38 distinct procedure/service records.
Ad
Practice Information
- Specialty Dermatology
- Other Specialties Dermatology
- Location Wauwatosa, WI
- Active Since 10/16/2006
- Last Updated 07/26/2022
- Taxonomy Code 207N00000X
- Entity Type Individual
- NPI Number 1790865806
Products in Payments
- TREMFYA (Drug) $63,754
- Enbrel (Biological) $51,315
- TALTZ (Drug) $41,866
- COSENTYX (Biological) $34,317
- Humira (Biological) $27,040
- Tremfya (Drug) $22,483
- AIN457A (Biological) $14,723
- Bimzelx (Biological) $13,171
- SILIQ (Drug) $11,644
- SPEVIGO (Drug) $8,862
- STELARA (Biological) $8,325
- SAR441169 (Drug) $7,517
- ORENCIA (Biological) $4,250
- Cimzia (Drug) $2,615
- SKYRIZI (Biological) $1,815
- Otezla (Drug) $1,438
- ILUMYA (tildrakizumab-asmn) injection (Biological) $550.00
- OFEV (Drug) $521.79
- AIN457A_COSENTYX_DERMATOLOGY (Biological) $356.21
- Sotyktu (Drug) $79.97
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Dermatology Doctors in Wauwatosa
Keri Chaney, M.d, M.D
Dermatology — Payments: $19,766
Dermatology $19,766
Dr. Edit Olasz Harken, M.d., Ph.d, M.D., PH.D
Dermatology — Payments: $7,122
Dermatology $7,122
Daniel Knabel, M.d, M.D
Dermatology — Payments: $1,074
Dermatology $1,074
Gretchen Roth, Md, MD
Dermatology — Payments: $661.28
Dermatology $661.28
Keely Marshall, M.d, M.D
Dermatology — Payments: $566.29
Dermatology $566.29
Dr. Melanie Clark, M.d, M.D
Dermatology — Payments: $123.03
Dermatology $123.03